BRG Borregaard

Borregaard ASA: EBITDA1 of NOK 398 million in the 4th quarter

Borregaard ASA: EBITDA1 of NOK 398 million in the 4th quarter

Borregaard’s operating revenues were NOK 1,744 million (NOK 1,605 million)2 in the 4th quarter of 2024. EBITDA1 reached NOK 398 million (NOK 327 million). The result in BioSolutions increased compared with the 4th quarter of 2023. BioMaterials remained at the same level, while there was a decrease in Fine Chemicals.



Increased sales were the main reason for the strong result in BioSolutions. For BioMaterials, higher sales volume and an improved product mix of speciality cellulose were offset by increased wood costs. Lower deliveries were the main reason for the weaker result in Fine Chemicals. The net currency effects were positive.

Other income and expenses1 were NOK -30 million in the 4th quarter of 2024. This accrual was for remediation of contaminated soil at the Sarpsborg site.

Profit before tax was NOK 170 million (NOK 135 million). Earnings per share were NOK 1.30 (NOK 1.20).

Full year 2024

Operating revenues increased to NOK 7,617 million (NOK 7,132 million). EBITDA1 reached an all-time high of NOK 1,874 million (NOK 1,781 million). Profit before tax was NOK 1,079 million (NOK 1,124 million). Earnings per share were NOK 8.25 (NOK 8.73).

- We are pleased to report an all-time high result for 2024. Our specialisation strategy has proven resilient amid challenging macroeconomic and geopolitical conditions, says President and CEO Per A. Sørlie.

Contacts:

Director Investor Relations, Knut-Harald Bakke, +47 905 79 164

Director Communications, Tone Horvei Bredal, +47 924 67 711

1. Operating profit before depreciation, amortisation and other income and expenses

2. Figures in parentheses are for the corresponding period in the preceding year

This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to Section 5 – 12 of the Norwegian Securities Trading Act.

This stock exchange announcement was published by Lotte Kvinlaug, Investor Relations Officer at Borregaard ASA, on 29 January 2025 at 07:00 CET.



Attachments



EN
29/01/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Borregaard

 PRESS RELEASE

Borregaard ASA: Shares for employees 2025

Borregaard ASA: Shares for employees 2025 3 February 2025: Borregaard ASA (“Borregaard”, OSE ticker: BRG) Borregaard employees have been given the opportunity to buy shares at a discounted price. The offer is valid from 3 February up to and including 7 February 2025. The price per share will be equal to the average volume weighted market price on 7 February 2025, with a 25% discount. Under the programme, employees may buy shares for a total amount of either NOK 5 000, NOK 15 000, NOK 25 000, NOK 40 000, NOK 55 000, or NOK 74 000. Contact:Lotte Kvinlaug, Investor Relations Officer, ...

Niclas Gehin
  • Niclas Gehin

Borregaard (Buy, TP: NOK240.00) - Price increases and FX tailwinds

Q4 EBITDA was NOK398m, beating our estimate by 12% and consensus by 10%, largely driven by a strong quarter for BioSolutions. While Fine Chemicals is set to face pricing headwinds due to increased supply from Eastern Europe, we believe these challenges should be more than offset by incoming FX tailwinds and pricing adjustments in BioMaterials. We have raised our 2025–2026e EPS by 4%. We reiterate our BUY and have increased our target price to NOK240 (230).

ABGSC Pulp & Paper Research ... (+3)
  • ABGSC Pulp & Paper Research
  • Ali Shemmari
  • Martin Melbye
ABGSC Pulp & Paper Research ... (+3)
  • ABGSC Pulp & Paper Research
  • Ali Shemmari
  • Martin Melbye
 PRESS RELEASE

Borregaard ASA: EBITDA1 of NOK 398 million in the 4th quarter

Borregaard ASA: EBITDA1 of NOK 398 million in the 4th quarter Borregaard’s operating revenues were NOK 1,744 million (NOK 1,605 million)2 in the 4th quarter of 2024. EBITDA1 reached NOK 398 million (NOK 327 million). The result in BioSolutions increased compared with the 4th quarter of 2023. BioMaterials remained at the same level, while there was a decrease in Fine Chemicals.Increased sales were the main reason for the strong result in BioSolutions. For BioMaterials, higher sales volume and an improved product mix of speciality cellulose were offset by increased wood costs. Lower deliverie...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch